Clinical Characteristics of HIV-Infected Patients with Venous Thromboembolism and Different CD4+ T Lymphocyte Levels
Yan-Fen Tang,Yu Wang,Tian-Jiao Xue,Gang Liu,Qi Chen,Wen Zhao,Yan-Yan Liu,Rong-Qian Chen,Li Chen,Jing Liu
DOI: https://doi.org/10.2147/jir.s346200
IF: 4.5
2022-01-28
Journal of Inflammation Research
Abstract:Yan-Fen Tang, 1, 2, &ast Yu Wang, 1, 2, &ast Tian-Jiao Xue, 1, 2 Gang Liu, 1, 2 Qi Chen, 1, 2 Wen Zhao, 1, 2 Yan-Yan Liu, 1, 2 Rong-Qian Chen, 1, 2 Li Chen, 1, 2 Jing Liu 1, 2 1 Department of Respiratory, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China; 2 Clinical Key Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yan-Fen Tang Department of Respiratory, Beijing Ditan Hospital, Capital Medical University, No. 8, Jingshun Dongjie, Chaoyang District, Beijing, 100015, People's Republic of China Tel +86 10 84322963 Fax +86 10 84322146 Email Objective: This study aims to analyze the clinical characteristics of HIV-infected patients complicated with venous thromboembolism (VTE). Methods: Seventy HIV-infected patients complicated with VTE were enrolled from Beijing Ditan Hospital Capital Medical University from October 2009 to December 2020 and divided into two groups according to CD4 + . The clinical data of 70 patients were observed, including general conditions, laboratory indexes, viral load, antiretroviral therapy (ART) before the diagnosis of VTE, and thrombus treatment. Results: The patients were divided into two groups according to the CD4 + T lymphocyte count. There were 27 patients with a CD4 + T lymphocyte count ≥ 200 cells/ul, classified as group A (27/70, 38.6%), and there were 43 patients with a CD4 + T lymphocyte count < 200 cells/ul, classified as group B (43/70, 61.4%). In group B, these patients included 37 males and 6 females. The average age was 47.1± 12.1 years old. The average levels of the following indexes were: D-dimer, 3.5 mg/L (0.7, 6.9); total cholesterol, 4.4 mmol/L (3.3, 5.5); triglycerides, 1.4 mmol/L (0.9, 2.0); low density lipoprotein, 1.9 mmol/L (1.5,2.5); albumin, 31.8± 6.4 g/L; CD4+, 66 cells/ul (18, 127); viral load, 12347 copies/mL (27, 203936). Sixty-three patients (63/70, 90%) had started highly active ART (HAART) before VTE was diagnosed, 37 patients (37/70, 52.9%) were complicated with bacterial pneumonia, 16 patients had Mycobacterium tuberculosis (16/70, 22.9%), 13 patients had Pneumocystis carinii pneumonia (PCP) (13/70, 18.6%), and eight patients were complicated with cytomegalovirus (CMV) infection (8/70, 11.4%). Twenty-four patients had tumors, and 15 patients had HIV-related tumors (15/70, 21.4%). There were significant differences between the two groups in the time from the diagnosis of HIV to the discovery of thrombosis, the time from ART to the discovery of thrombosis and bacterial pneumonia, and the differences in WBC, PLT, Hb, CRP, PTA, INR, TCHO, LDL-C, ALB, and viral load were statistically significant. Conclusion: The prevalence of VTE in HIV-infected people in the last 11 years was 1.4%. In patients with a high viral load, CRP, D-dimer levels, and low CD4 + and albumin levels, 11.4– 22.9% were complicated with an opportunistic infection, and 21.4% had HIV-related tumors. There were significant differences between the two groups in high viral load, CRP, D-dimer, and low albumin. Keywords: HIV-infected persons, venous thromboembolism, CD4 + T lymphocytes, disease characteristics The clinical and economic burden of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is immense. In the United States, the average incidence rate of VTE is 123/10,000 persons per year, and it is 131/100,000 persons per year in Europe. 1 VTE is a complex multifactorial disease, influenced by acquired or inherited predispositions to thrombosis (eg, thrombophilia), environmental exposures (eg, clinical risk factors), and the interaction between them. The triad includes changes in the constituency of blood (hypercoagulability), changes in the vessel wall (injury), and changes in the pattern of blood flow (venous stasis). The causes for VTE are multifactorial and are not readily apparent in many cases. These physiologic changes can occur as a result of pathology, therapies, and treatments. The following are considered strong risk factors that may predispose someone to VTE: Venous stasis; Hypercoagulable states; Immobilization; Surgery and trauma; Pregnancy; Oral contraceptives and estrogen replacement; and Malignancy. With the development of modern antiretroviral therapy (ART), human immunodeficiency vi -Abstract Truncated-
immunology